(SPYU) MAX S P 500 4X Leveraged ETN - Overview
Etf: Leveraged, Index, Daily, Trading, ETN
| Risk 5d forecast | |
|---|---|
| Volatility | 60.9% |
| Relative Tail Risk | 4.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.41 |
| Alpha | -38.24 |
| Character TTM | |
|---|---|
| Beta | 3.780 |
| Beta Downside | 3.824 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.27% |
| CAGR/Max DD | 0.73 |
Description: SPYU MAX S P 500 4X Leveraged ETN December 29, 2025
The MAX S&P 500 4X Leveraged ETN (NYSE ARCA: SPYU) is marketed as a daily-trading instrument for sophisticated investors seeking a four-times long exposure to the S&P 500’s daily performance. It explicitly states that returns are calculated before deducting the Daily Investor Fee, Daily Financing Charge, and any Redemption Fee, meaning actual investor outcomes will be lower than the quoted leverage factor.
Key quantitative points to consider (as of the most recent data):
• Expense ratio ≈ 0.95% p.a., which is higher than traditional ETFs and erodes returns over time.
• Average daily trading volume ≈ 1.2 million shares, indicating decent liquidity but also potential for price slippage in volatile markets.
• Sensitivity to market volatility: a 1% rise in the VIX typically reduces the ETN’s effective leverage by ~0.1–0.2% due to financing costs, illustrating the “volatility drag” inherent in leveraged products.
These drivers suggest that SPYU’s performance is heavily contingent on short-term equity momentum, U.S. monetary-policy shifts (e.g., Fed rate changes), and the tech-heavy composition of the S&P 500.
If you want a deeper, data-driven assessment of how SPYU behaves under different market regimes, a quick look at ValueRay’s analytics can help you quantify the decay risk and compare it to alternative leveraged instruments.
What is the price of SPYU shares?
Over the past week, the price has changed by -1.56%, over one month by -3.89%, over three months by +4.12% and over the past year by +8.12%.
Is SPYU a buy, sell or hold?
What are the forecasts/targets for the SPYU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 62.4 | 12% |
SPYU Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 451.9m USD (451.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 451.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 451.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 19.85% (E(451.9m)/V(451.9m) * Re(19.85%) + (debt-free company))
Discount Rate = 19.85% (= CAPM, Blume Beta Adj.) -> capped to 17.85%
Fair Price DCF = unknown (Cash Flow 0.0)